Bristol-Myers Squibb Co BMY
News
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Bristol-Myers Squibb Down Over 6%, On Track for Largest Percent Decrease Since March 2020 — Data Talk
Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts
Bristol Myers Shedding 2,200 Jobs in Cost Savings Push
Bristol Myers Squibb shares fall amid sluggish sales of some newer drugs
Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster